Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex
Amélie Penot(Centre Hospitalier Universitaire de Limoges), A. Jaccard(Contrôle de la Réponse Immune B et Lymphoproliférations), J. Abraham, Brigitte Kolb(Centre Hospitalier Universitaire de Reims), Éstelle Desport(Centre Hospitalier Universitaire de Poitiers), Xavier Leleu(Inserm), Houria Debarri(Centre Hospitalier Universitaire de Lille), David Lavergne, Frank Bridoux(Université de Poitiers), Claire Aguilar(Hôpital Necker-Enfants Malades), V. Leblond(Université Sorbonne Nouvelle), Jean‐Paul Fermand(Sorbonne Université), A. Goldstein(Centre Hospitalier du Mans), F. Auroy
Cited by 3
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719